Latest Patent Applications News

TG Metals has expanded its Van Uden gold resource to 270,800 ounces with a 120% increase in indicated ounces, discovered new mineralisation 550m south, and filed a lithium processing patent at Lake Johnston.

Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Phoslock Environmental Technologies reported a stable sales volume and improved cash flow compared to last year, while ramping up production after reopening its Chinese factory. The company is advancing R&D on a new lanthanum product and faces ongoing legal challenges with mediation set for June.

WhiteHawk (ASX: WHK) has acquired Quixxi, gaining the Clarity AI platform to extend its cybersecurity services into the burgeoning global AI governance sector. The deal positions WhiteHawk at the convergence of cybersecurity, data governance, and AI risk management amid rapid market growth and regulatory momentum.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Cobalt Blue Holdings has confirmed its cobalt sulphate meets stringent battery precursor specifications, advancing its Kwinana Cobalt Refinery toward a Final Investment Decision. The company also expands its graphite recovery program, positioning itself at the forefront of Australia’s battery materials ecosystem.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.